Next 10 |
A look at the top 10 most actives in the United States Kaixin Holdings (KXIN) rose 171.5% to $0.3421 on volume of 647,176,435 shares iShares China Large-Cap ETF (FXI) rose 7.2% to $35.48 on volume of 213,691,731 shares NVIDIA Corporation (NVDA) rose 1.6% to $118.85 on volume of 208,742,004 ...
2024-10-02 10:55:37 ET More on Shattuck Labs Shattuck plunges after discontinuing lead candidate Seeking Alpha’s Quant Rating on Shattuck Labs Historical earnings data for Shattuck Labs Financial information for Shattuck Labs Read the full ar...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.7% to $117 on volume of 292,186,152 shares PROSHARES TRUST (SQQQ) rose 4.5% to $7.72 on volume of 213,073,959 shares Mangoceuticals Inc. (MGRX) rose 26.4% to $0.2984 on volume of 201,639,758 shares AgE...
2024-10-01 12:30:06 ET H.C. Wainwright analyst issues NEUTRAL recommendation for STTK on October 1, 2024 10:33AM ET. The previous analyst recommendation was Buy. STTK was trading at $1.9801 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
A look at the top 10 most actives in the United States AgEagle Aerial Systems Inc. (UAVS) rose 76.4% to $0.166 on volume of 113,158,480 shares Mangoceuticals Inc. (MGRX) rose 79.6% to $0.4238 on volume of 93,239,861 shares MicroCloud Hologram Inc. (HOLO) rose 18.9% to $0.4282 on volume of 5...
2024-10-01 08:16:10 ET More on Shattuck Labs Seeking Alpha’s Quant Rating on Shattuck Labs Historical earnings data for Shattuck Labs Financial information for Shattuck Labs Read the full article on Seeking Alpha For further details see: Sh...
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further dev...
2024-08-02 10:32:41 ET More on Shattuck Labs Hold For Now: Shattuck Labs' SL-172154 Potential In Early Trials Shattuck gains on early-stage data update for lead asset in blood cancer Seeking Alpha’s Quant Rating on Shattuck Labs Historical earnings dat...
– Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients at the European Society of ...
AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmu...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Kaixin Holdings (KXIN) rose 171.5% to $0.3421 on volume of 647,176,435 shares iShares China Large-Cap ETF (FXI) rose 7.2% to $35.48 on volume of 213,691,731 shares NVIDIA Corporation (NVDA) rose 1.6% to $118.85 on volume of 208,742,004 ...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.7% to $117 on volume of 292,186,152 shares PROSHARES TRUST (SQQQ) rose 4.5% to $7.72 on volume of 213,073,959 shares Mangoceuticals Inc. (MGRX) rose 26.4% to $0.2984 on volume of 201,639,758 shares AgE...
2024-10-01 12:30:06 ET H.C. Wainwright analyst issues NEUTRAL recommendation for STTK on October 1, 2024 10:33AM ET. The previous analyst recommendation was Buy. STTK was trading at $1.9801 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...